J. Safra Sarasin Holding’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$378K Hold
25,500
0.01% 437
2025
Q4
$407K Hold
25,500
0.01% 417
2025
Q3
$282K Hold
25,500
﹤0.01% 444
2025
Q2
$216K Hold
25,500
﹤0.01% 477
2025
Q1
$205K Hold
25,500
﹤0.01% 473
2024
Q4
$229K Hold
25,500
﹤0.01% 451
2024
Q3
$187K Hold
25,500
﹤0.01% 434
2024
Q2
$146K Buy
+25,500
New +$134K ﹤0.01% 452

Other funds holding AUPH

J. Safra Sarasin Holding's AUPH Position: Q1 2026 in Review

J. Safra Sarasin Holding held its Aurinia Pharmaceuticals (AUPH) position steady in Q1 2026 at 25,500 shares worth $378K. The position accounts for 0.01% of the portfolio, ranked #437.

J. Safra Sarasin Holding first reported a position in AUPH in Q2 2024 and has held it in 8 quarters since. The position peaked at $407K in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • J. Safra Sarasin Holding held 25,500 shares of Aurinia Pharmaceuticals worth $378K as of Q1 2026.
  • J. Safra Sarasin Holding left its Aurinia Pharmaceuticals share count unchanged in Q1 2026.
  • Aurinia Pharmaceuticals made up 0.01% of J. Safra Sarasin Holding's portfolio in Q1 2026, its #437 holding.
  • J. Safra Sarasin Holding first reported a position in Aurinia Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • J. Safra Sarasin Holding's Aurinia Pharmaceuticals position peaked at $407K in Q4 2025.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q1 2026, filed 4 May 2026.